Other

Asubio Pharma Co. Ltd.

Suntory Limited

Mayumi Furuya

Keijiro Sugimura

Kazutoshi Miyazawa

Etsuo Nakagawa

Hiroyuki Takeuchi

Shuichi Matsui

Ryuichi Morishita

Yasuhiro Kubo

Yasuyuki Sasada

Hisayuki Matsuo

Shoji Tanaka

Yoshiharu Minamitake

Fumiyuki Hattori

Naruto Katsuragi

Yasuo Kitajima

Kayoko Kawashima

Katsuyuki Kawano

The present invention provides methods for screening drugs inhibiting the expression of OSF-2 gene or the production or function of the protein encoded thereby and therapeutic agents for heart failure having such effects. Useful methods for diagnosing heart failure can be provided by monitoring the expression or variation of said gene or the production of the protein encoded thereby. The present invention also provides transgenic animals with forced expression of OSF-2 gene and methods for studying changes in gene expression or protein production or the functions of various genes or proteins with the progress of the pathology of heart failure using them and novel therapeutic agents for heart failure.

Remedies for heart failure

A prophylactic or therapeutic method for a disease associated with decreased expression of AOP-1 gene or AOP-1, comprising (1) transfecting a nucleic acid encoding AOP-1 or a nucleic acid encoding a polypeptide having an addition, deletion or substitution of one or more amino acids as compared with the amino acid sequence of AOP-1 while retaining the function of AOP-1, or (2) administering a material enhancing the expression of AOP-1 gene, a material enhancing the production of AOP-1 or a material enhancing the function of AOP-1.

Therapeutic methods and agents for diseases associated with decreased expression of AOP-1 gene or AOP-1

Liquid crystalline compound having difluoropropyleneoxy group as bonding group, liquid crystal composition and liquid crystal display element

Novel peptides represented by the general formula: ##STR1## and physiologically acceptable acid addition salts thereof; where (A) represents H-, H-Gly, H-Lys-Gly, H-Ser-Lys-Gly, H-Leu-Ser-Lys-Gly, H-Gly-Leu-Ser-Lys-Gly, H-ser, H-Ser-Ser, H-Arg-Ser-Ser, H-Arg-Arg-Ser-Ser, H-Leu-Arg-Arg-Ser-Ser, H-Ser-Leu-Arg-Arg-Ser-Ser; (B) represents H-Cys or Pmp; (C) represents Phe-, pCl-Phe, pF-Phe, pNO.sub.2 -Phe or Cha; (D) represents Ile, Val, Aib, tLeu, Gly or Leu; (E) represents Lys or Arg; (F) represents Ile, Leu or Met; (G) represents Ser or Ala; (H) represents Met or Gln; (I) represents --OH, -Asn-OH, -Asn-Ser-OH, -Asn-Ser-Phe-OH, -Asn-Ser-Phe-Arg-OH or -Asn-Ser-Phe-Arg-Tyr-OH; and the symbol ' . . . ' represents a disulfide bond; provided that 1) .alpha.-hANP, 2) .alpha.-hANP (7-28) and 3) CNP-22 are excluded from the scope of that general formula. Also disclosed are agents for suppressing the growth of vascular smooth muscle cells that contains those peptides as effective ingredients.

CNP analog peptides and their use

Growing community of inventors

Osaka, Japan

Mayumi Furuya